We are pleased to announce an upcoming Special Issue of Psychopharmacology on Psychedelic Drugs.
The recent surge of interest in the use of psychedelics in neuropsychiatric disorders has raised a host of important questions. Researchers and clinicians are searching for the optimal drugs, doses and dosing regimens, as well as for the target symptoms and behaviors that respond most effectively to treatment with these drugs. Other scientists are seeking to understand the molecular mechanisms by which psychedelic drugs act to change perception, cognitive function and mood. The science behind psychedelic drugs is in its infancy, and much remains to be learned about how to optimize their extraordinary effects for therapeutic benefit, or for personal growth and enhancement. At the same time, this new branch of research raises questions about ethical and regulatory issues, about synergistic interactions between psychotherapy and drugs, and about the role of context and expectancies in beneficial effects.
We are excited to invite you to contribute to a special issue of Psychopharmacology on Psychedelics. We welcome both review articles and empirical papers, including submissions from all types of research including mechanisms, brain imaging, immune function, therapeutic potential, cognition, abuse liability and regulatory issues.
Please notify co-editors Cyril D’Souza or Harriet de Wit by April 15, 2021 if you would like to contribute to this Special Issue. Final submissions will be due Sept 30, 2021. Please contact the editors if you have questions.